This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 1 week ago
Diabetes Injection Pens Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
Diabetes is a metabolic disease in which person has high blood glucose level due to inadequate insulin production or resistant of body cells to insulin. Majorly, diabetes is in three form: type 1 diabetes, type 2 diabetes, and gestational diabetes.Press Release Ping, 10 hours ago A growing market for diabetes SlideShare.net, 2 weeks ago
A diabetes drug made from a chemical found in the spit of a venomous lizard may be the latest weapon in the battle against obesity. Byetta has been used in the US to treat type 2 diabetes since 2005. The active ingredient is derived from the ...ZimbabweNation.com, 1 day ago
Full-Year and Q4 2015 Results Financial Summary FY 2015 Q4 2015 ------------------ ------------------------- ------------------------ $m % change $m % change ------------------ ------- ---------------- ------ ---------------- CER(1) Actual ...ADVFN UK, 4 days ago
Operator Welcome to Apollo Global Management Fourth Quarter and FY 15 Earnings Conference Call. [Operator Instructions]. And, following managements prepared remarks, this call will be open for questions. This conference call is being recorded. I ...Seeking Alpha, 4 days ago
Drug Pricing In The U.S. Under Pressure From Multiple Fronts - Is It Time To Stay Away From Innovator Pharma?
The US has always been the darling of global pharma innovators as they have been able to fetch premium pricing for their novel drugs. Most drugs sold in the US are sold at a significant premium to the prices they fetch in other developed markets ...Seeking Alpha, 1 week ago
Glide Technologies Announces Successful Proof-of-Concept with Novel Exenatide Solid Dose Formulation
Make An Enquiry Glide Technologies has announced that they have successfully completed a pre-clinical proof-of-concept study with its novel solid dose formulation of exenatide, a GLP-1 agonist for the treatment of Type 2 diabetes. Results ...Pharmaceutical Technology, 1 week ago
More from: BioSpace, PR Newswire...and 32 other sources
An innovative technique for resetting the bone of a nineyear- old boy born with a serious congenital defect in which his thigh was backwards has been successfully repaired. The rotationplasty was carried out at Bnei Brak's Maayanei Hayeshua Medical ...Jerusalem Post, 3 weeks ago
FDA Drug Safety Communication: FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients
In an effort to reduce the serious risk of infection spread through sharing of multi-dose diabetes pen devices intended for single patient use only, the U.S. Food and Drug Administration (FDA) is requiring additional label warnings prohibiting ...U.S. Food and Drug Administration, 3 weeks ago
A new evidence review compares the weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes. Three of the drugs are marketed in the United States, including dulaglutide (Trulicity), once weekly exenatide ...AHC Media, 3 weeks ago Once-a-week diabetes drugs are similar in safety and effectiveness Naija247News, 2 months ago Once-a-week diabetes meds are similar in safety and effectiveness Yahoo! India, 2 months ago Study: Five once-a-week diabetes drugs all safe, effective MyInforms, 2 months ago
on your WebpageAdd Widget >Get your members hooked!